The differentiation of primary hemophagocytic lymphohistiocytosis (pHLH) and macrophage activation syndrome (MAS) poses a challenge to hematologists. The aim of this study was (1) to compare the levels of soluble ST2 (sST2), sCD163, IFN-gamma, IL-10, IL-18, TNF-alpha and Serum soluble interleukin-2 receptor (sCD25) in patients with pHLH and MAS and (2) to investigate whether they can help differentiate the two diseases. A total of 52 participants were recruited in this study, including 12 pHLH patients, 20 MAS patients, and 20 healthy subjects. We measured the levels of sST2, sCD163 and sCD25 in serum by ELISA. The serum levels of IFN-gamma, IL-10, IL-18, and TNF-alpha were detected using a Luminex 200 instrument. The serum levels of sST2 and sCD163 in MAS patients were markedly higher than that in pHLH patients (363.13 +/- 307.24 ng/ml vs 80.75 +/- 87.04 ng/ml, P = 0.004; 3532.72 +/- 2479.68 ng/ml vs 1731.96 +/- 1262.07 ng/ml, P = 0.046). There was no significant difference in the expression of IFN-gamma (306.89 +/- 281.60 pg/ml vs 562.43 +/- 399.86 pg/ml), IL-10 (20.40 +/- 30.49 pg/ml vs 8.3 +/- 13.14 pg/ml), IL-18 (463.33 +/- 597.04 pg/ml vs 1247.82 +/- 1318.58 pg/ml), TNF-alpha (61.48 +/- 84.69 pg/ml vs 106.10 +/- 77.21 pg/ml), and sCD25 (21062.1 +/- 18515.26 pg/ml vs 11074.78 +/- 11149.96 pg/ml) between pHLH and MAS. Patients with pHLH and MAS show some differences in cytokine profiles. The elevated levels of IFN-gamma, IL- 10, TNF-alpha, IL-18, and sCD25 can contribute to the diagnosis of HLH, but may not discriminate pHLH from MAS. Levels of sST2 and sCD163 may serve as markers to distinguish pHLH from MAS.
基金：
Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding [ZYLX201702]; Beijing Municipal Administration of Hospitals' Ascent Plan [DFL20180101]; Beijing Natural Science FoundationBeijing Natural Science Foundation [7181003]
第一作者单位：[1]Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
通讯作者：
通讯机构：[1]Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China[*1]Department of Hematology, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xicheng District, Beijing 100050, China
推荐引用方式(GB/T 7714)：
Gao Zhuo,Wang Yini,Wang Jingshi,et al.Soluble ST2 and CD163 as Potential Biomarkers to Differentiate Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome[J].MEDITERRANEAN JOURNAL of HEMATOLOGY and INFECTIOUS DISEASES.2019,11:doi:10.4084/MJHID.2019.008.
APA：
Gao, Zhuo,Wang, Yini,Wang, Jingshi,Zhang, Jia&Wang, Zhao.(2019).Soluble ST2 and CD163 as Potential Biomarkers to Differentiate Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome.MEDITERRANEAN JOURNAL of HEMATOLOGY and INFECTIOUS DISEASES,11,
MLA：
Gao, Zhuo,et al."Soluble ST2 and CD163 as Potential Biomarkers to Differentiate Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome".MEDITERRANEAN JOURNAL of HEMATOLOGY and INFECTIOUS DISEASES 11.(2019)
